vs
Ardmore Shipping Corp（ASC）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是Ardmore Shipping Corp的1.1倍（$92.9M vs $81.2M），Vericel Corp净利率更高（25.0% vs 15.7%，领先9.3%），Vericel Corp同比增速更快（23.3% vs -15.5%），过去两年Vericel Corp的营收复合增速更高（34.6% vs -6.0%）
阿德莫尔航运是一家全球化海上运输企业，持有并运营中型成品油轮与化学品运输船队，可为全球能源、化工及贸易领域客户提供石油产品、特种化学品及其他散装液态货物的海运服务。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
ASC vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.1倍
$81.2M
营收增速更快
VCEL
高出38.7%
-15.5%
净利率更高
VCEL
高出9.3%
15.7%
两年增速更快
VCEL
近两年复合增速
-6.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $81.2M | $92.9M |
| 净利润 | $12.8M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 16.1% | 24.1% |
| 净利率 | 15.7% | 25.0% |
| 营收同比 | -15.5% | 23.3% |
| 净利润同比 | -47.0% | 17.3% |
| 每股收益（稀释后） | $0.30 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASCVCEL
| Q4 25 | — | $92.9M | ||
| Q3 25 | $81.2M | $67.5M | ||
| Q2 25 | $72.0M | $63.2M | ||
| Q1 25 | $74.0M | $52.6M | ||
| Q4 24 | — | $75.4M | ||
| Q3 24 | $96.1M | $57.9M | ||
| Q2 24 | $121.3M | $52.7M | ||
| Q1 24 | $106.3M | $51.3M |
净利润ASCVCEL
| Q4 25 | — | $23.2M | ||
| Q3 25 | $12.8M | $5.1M | ||
| Q2 25 | $9.6M | $-553.0K | ||
| Q1 25 | $6.3M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $24.1M | $-901.0K | ||
| Q2 24 | $62.7M | $-4.7M | ||
| Q1 24 | $39.2M | $-3.9M |
毛利率ASCVCEL
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
营业利润率ASCVCEL
| Q4 25 | — | 24.1% | ||
| Q3 25 | 16.1% | 5.1% | ||
| Q2 25 | 13.5% | -3.2% | ||
| Q1 25 | 8.6% | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 25.4% | -4.3% | ||
| Q2 24 | 51.3% | -11.5% | ||
| Q1 24 | 37.2% | -10.7% |
净利率ASCVCEL
| Q4 25 | — | 25.0% | ||
| Q3 25 | 15.7% | 7.5% | ||
| Q2 25 | 13.3% | -0.9% | ||
| Q1 25 | 8.5% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 25.1% | -1.6% | ||
| Q2 24 | 51.7% | -8.9% | ||
| Q1 24 | 36.9% | -7.5% |
每股收益（稀释后）ASCVCEL
| Q4 25 | — | $0.46 | ||
| Q3 25 | $0.30 | $0.10 | ||
| Q2 25 | $0.22 | $-0.01 | ||
| Q1 25 | $0.14 | $-0.23 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $0.55 | $-0.02 | ||
| Q2 24 | $1.47 | $-0.10 | ||
| Q1 24 | $0.92 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $137.5M |
| 总债务越低越好 | $116.1M | — |
| 股东权益账面价值 | $628.2M | $354.6M |
| 总资产 | $799.8M | $488.0M |
| 负债/权益比越低杠杆越低 | 0.18× | — |
8季度趋势，按日历期对齐
现金及短期投资ASCVCEL
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
总债务ASCVCEL
| Q4 25 | — | — | ||
| Q3 25 | $116.1M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $44.2M | — | ||
| Q1 24 | $23.1M | — |
股东权益ASCVCEL
| Q4 25 | — | $354.6M | ||
| Q3 25 | $628.2M | $321.9M | ||
| Q2 25 | $618.3M | $306.8M | ||
| Q1 25 | $610.7M | $295.5M | ||
| Q4 24 | — | $292.0M | ||
| Q3 24 | $627.0M | $257.5M | ||
| Q2 24 | $617.7M | $243.0M | ||
| Q1 24 | $567.9M | $233.9M |
总资产ASCVCEL
| Q4 25 | — | $488.0M | ||
| Q3 25 | $799.8M | $453.3M | ||
| Q2 25 | $703.8M | $435.6M | ||
| Q1 25 | $690.4M | $424.6M | ||
| Q4 24 | — | $432.7M | ||
| Q3 24 | $722.8M | $390.4M | ||
| Q2 24 | $742.0M | $376.8M | ||
| Q1 24 | $704.1M | $356.7M |
负债/权益比ASCVCEL
| Q4 25 | — | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.9M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | — | $12.8M |
| 自由现金流率自由现金流/营收 | — | 13.8% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | 1.40× | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流ASCVCEL
| Q4 25 | — | $15.0M | ||
| Q3 25 | $17.9M | $22.1M | ||
| Q2 25 | $11.2M | $8.2M | ||
| Q1 25 | $26.3M | $6.6M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | $39.9M | $10.2M | ||
| Q2 24 | $48.4M | $18.5M | ||
| Q1 24 | $49.2M | $7.2M |
自由现金流ASCVCEL
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
自由现金流率ASCVCEL
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
资本支出强度ASCVCEL
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
现金转化率ASCVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | 1.40× | 4.35× | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 4.20× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASC
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
